3 186

Cited 18 times in

Safety of Everolimus by Treatment Duration in Patients With Advanced Renal Cell Cancer in an Expanded Access Program

DC FieldValueLanguage
dc.contributor.author라선영-
dc.date.accessioned2014-12-18T08:35:11Z-
dc.date.available2014-12-18T08:35:11Z-
dc.date.issued2013-
dc.identifier.issn0090-4295-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/86583-
dc.description.abstractOBJECTIVE: To retrospectively analyze the effects of treatment duration on outcomes of everolimus treatment of patients in the RAD001 Expanded-Access Clinical Trial in RCC (REACT) program. METHODS: Patients with metastatic renal cell carcinoma refractory to vascular endothelial growth factor receptor-tyrosine kinase inhibitor received everolimus (10 mg once daily), with dosing interruption or modifications allowed for toxicity. All serious and grade 3/4 adverse events and grade 1/2 adverse events leading to a change in drug administration were reported. Tumor response was evaluated using Response Evaluation Criteria In Solid Tumors. RESULTS: The study stratified 1367 evaluable patients into treatment duration groups of <3 months, ≥3 and <6 months, ≥6 months and <1 year, and ≥1 year. Pneumonia, noninfectious pneumonitis, and hyperglycemia occurred more frequently in patients receiving everolimus for ≥1 year but did not result in treatment discontinuations. First occurrence of adverse events presented early in the treatment course for most patients. Treatment duration of ≥6 months was associated with improved disease control rates. CONCLUSION: Everolimus is well tolerated in patients with metastatic renal cell carcinoma for treatment durations≥1 year and not associated with cumulative toxicity.-
dc.description.statementOfResponsibilityopen-
dc.relation.isPartOfUROLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAged-
dc.subject.MESHAnemia/chemically induced-
dc.subject.MESHAntineoplastic Agents/adverse effects*-
dc.subject.MESHAntineoplastic Agents/therapeutic use-
dc.subject.MESHCarcinoma, Renal Cell/drug therapy*-
dc.subject.MESHCarcinoma, Renal Cell/secondary-
dc.subject.MESHDisease Progression-
dc.subject.MESHDyspnea/chemically induced-
dc.subject.MESHEverolimus-
dc.subject.MESHFatigue/chemically induced-
dc.subject.MESHFemale-
dc.subject.MESHHumans-
dc.subject.MESHHyperglycemia/chemically induced-
dc.subject.MESHKidney Neoplasms/drug therapy*-
dc.subject.MESHKidney Neoplasms/pathology-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHPneumonia/chemically induced-
dc.subject.MESHSirolimus/adverse effects-
dc.subject.MESHSirolimus/analogs & derivatives*-
dc.subject.MESHSirolimus/therapeutic use-
dc.subject.MESHStomatitis/chemically induced-
dc.subject.MESHTime Factors-
dc.subject.MESHTreatment Outcome-
dc.titleSafety of Everolimus by Treatment Duration in Patients With Advanced Renal Cell Cancer in an Expanded Access Program-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학)-
dc.contributor.googleauthorAlfonsus J.M. van den Eertwegh-
dc.contributor.googleauthorPierre Karakiewicz-
dc.contributor.googleauthorSevil Bavbek-
dc.contributor.googleauthorSun Young Rha-
dc.contributor.googleauthorSergio Bracarda-
dc.contributor.googleauthorAmit Bahl-
dc.contributor.googleauthorYen-chuan Ou-
dc.contributor.googleauthorDennis Kim-
dc.contributor.googleauthorAshok Panneerselvam-
dc.contributor.googleauthorOezlem Anak-
dc.contributor.googleauthorViktor Grünwald-
dc.identifier.doi10.1016/j.urology.2012.09.019-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA01316-
dc.relation.journalcodeJ02775-
dc.identifier.eissn1527-9995-
dc.identifier.pmid23273080-
dc.identifier.urlhttp://www.sciencedirect.com/science/article/pii/S0090429512011107-
dc.subject.keywordAged-
dc.subject.keywordAnemia/chemically induced-
dc.subject.keywordAntineoplastic Agents/adverse effects*-
dc.subject.keywordAntineoplastic Agents/therapeutic use-
dc.subject.keywordCarcinoma, Renal Cell/drug therapy*-
dc.subject.keywordCarcinoma, Renal Cell/secondary-
dc.subject.keywordDisease Progression-
dc.subject.keywordDyspnea/chemically induced-
dc.subject.keywordEverolimus-
dc.subject.keywordFatigue/chemically induced-
dc.subject.keywordFemale-
dc.subject.keywordHumans-
dc.subject.keywordHyperglycemia/chemically induced-
dc.subject.keywordKidney Neoplasms/drug therapy*-
dc.subject.keywordKidney Neoplasms/pathology-
dc.subject.keywordMale-
dc.subject.keywordMiddle Aged-
dc.subject.keywordPneumonia/chemically induced-
dc.subject.keywordSirolimus/adverse effects-
dc.subject.keywordSirolimus/analogs & derivatives*-
dc.subject.keywordSirolimus/therapeutic use-
dc.subject.keywordStomatitis/chemically induced-
dc.subject.keywordTime Factors-
dc.subject.keywordTreatment Outcome-
dc.contributor.alternativeNameRha, Sun Young-
dc.contributor.affiliatedAuthorRha, Sun Young-
dc.rights.accessRightsnot free-
dc.citation.volume81-
dc.citation.number1-
dc.citation.startPage143-
dc.citation.endPage149-
dc.identifier.bibliographicCitationUROLOGY, Vol.81(1) : 143-149, 2013-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.